Molecular Partners narrows focus to radiotherapy, plans workforce cuts

Molecular Partners reported third-quarter 2026 results on October 29, 2026, alongside what it called corporate highlights and unaudited financial results for the third quarter, along with a deepened focus on radiopharmaceuticals and streamlining of its resources.¹

The company's lead program, MP0712, a DLL3-targeting Radio-DARPin carrying the alpha-emitting payload 212Pb, is being co-developed with Orano Med for small cell lung cancer and other neuroendocrine cancers.¹ In the Phase 1/2a study (NCT07278479), dosing is ongoing in the fully recruited dose level 2 at 105 MBq per dose, with 8 of 9 planned sites open.¹ All patients in dose level 1 at 75 MBq passed the safety observation period with no dose-limiting events, and all adverse events reported so far were mild to moderate and transient.¹ Initial safety data are set for presentation at the IASLC/ASCO North America Conference on Lung Cancer in December 2026, and efficacy data are expected in 2027.¹

Reflecting this focus, the company has told Kanton Zürich's Office for Economic Affairs of its intention to cut its workforce by up to 55 positions, or as much as 44% of staff,¹ with full implementation expected by the second quarter of 2027 and related cost savings fully effective early in the second half of 2027.¹ The financial impact is not yet estimable, the company said.

Other pipeline items: MSLN-targeting MP0726 is moving toward first-in-human imaging in the second half of 2026,¹ while newly nominated CD70-targeting MP0730 is anticipated to start its first-in-human program in mid-2027.¹

On finances, the company reported cash and cash equivalents of CHF 57.5 million, or about USD 69 million, as of September 30, 2026, which it said should be sufficient to fund operations into late 2027.¹